- Who We Are
- Service Areas
- Research Areas
Over 100 biotech, pharmaceutical, and medical device firms rely on Flagship’s tissue analysis to advance emerging therapies into and through regulatory processes. Tissue analysis plays a crucial role in many phases of drug discovery, development, and clinical trials. Flagship is pioneering a novel approach to pathology that combines scientific expertise with digital technologies that are accelerating and refining the entire pathology process to be more precise at every step.
To ensure the quality our customers need when measuring tissue, our team has developed a complete pathology service including tissue sourcing, histology, custom image analysis, biostatistics, and pathology reports. Projects range from early stage, exploratory, and tissue microarray studies through large, late stage, CLIA-based clinical trials or IDE image analysis companion diagnostics filings. Flagship is platform agnostic on both image analysis and in immunohistochemistry or immunofluorescence, bringing the best solution to the particular client’s tissue challenge. Careful regulatory oversight and quality control have made Flagship a fast-growing leader in the delivery of pharmacodynamic endpoints, biomarker interpretation, and patient selection studies. We have the personnel and processes to scale projects from early small studies through diagnostic assay development and clinical trial evaluations.